Chicago, Illinois – August 3, 2026
Meitheal Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Garzulys™ (insulin aspart-fsan) injection, a biosimilar to NovoLog® (insulin aspart), for improving glycemic control in adults and pediatric patients with diabetes mellitus. The approval represents an important expansion of Meitheal’s biologics portfolio and strengthens the company’s presence in diabetes care. Garzulys is a rapid-acting human insulin analog approved for both subcutaneous and intravenous administration. Emerge Bioscience Pte. Ltd. holds the approved Biologics License Application for Garzulys, while Meitheal serves as the product’s U.S. Regulatory Agent and holds exclusive commercialization rights in the United States under its licensing agreement with Emerge.
FDA Approval Expands Meitheal’s Diabetes and Biologics Portfolio
The FDA approval of Garzulys marks a significant regulatory milestone for Meitheal as the company expands beyond its established generic injectable business into biologics and branded medicines. Founded in 2017, Meitheal has developed a diversified U.S. pharmaceutical platform supporting more than 80 FDA-approved products across therapeutic areas including diabetes, oncology, anti-infectives, anesthesia, critical care and fertility. Garzulys adds a rapid-acting insulin biosimilar to that portfolio and advances Meitheal’s strategy of building a broader presence in complex biologic medicines. Under its agreement with Emerge, Meitheal also holds exclusive U.S. commercialization rights for two additional insulin biosimilar candidates currently in development, creating the potential for further expansion of its diabetes portfolio. The company said it is investing in regulatory capabilities, commercial infrastructure and strategic partnerships to support broader patient access to biologic treatment options.
Garzulys Offers Rapid-Acting Insulin Biosimilar for Diabetes
Garzulys (insulin aspart-fsan) is biosimilar to NovoLog (insulin aspart) and is indicated to improve glycemic control in both adult and pediatric patients with diabetes mellitus. As a biosimilar, Garzulys was approved based on evidence demonstrating that the biological product is highly similar to its FDA-approved reference product with no clinically meaningful differences for the approved conditions of use, strengths, dosage forms and routes of administration. Garzulys can be administered subcutaneously or intravenously. Like other insulin products, treatment requires appropriate clinical management because hypoglycemia is the most common adverse effect of insulin therapy and severe episodes can lead to seizures, unconsciousness and potentially life-threatening outcomes. Other adverse reactions observed with Garzulys include allergic reactions, injection-site reactions, lipodystrophy, rash and pruritus. The prescribing information also includes precautions concerning medication errors, hypersensitivity, hypokalemia, changes in insulin regimens and insulin pump malfunction.
Advertisement
Global Collaboration Supports Garzulys U.S. Commercialization
The development and approval of Garzulys resulted from a multi-company global collaboration involving expertise across drug substance development, manufacturing, clinical development, regulatory affairs and supply-chain management. Tonghua Dongbao Pharmaceutical was responsible for drug substance development, while Nanjing King-Friend Biochemical Pharmaceutical handled drug product development. Xentria led the clinical development program, and Meitheal, acting as U.S. Regulatory Agent, led the regulatory activities supporting FDA approval. Emerge, the BLA holder, is responsible for key supply-chain activities associated with the product. The broader collaboration between Tonghua Dongbao and Nanjing King-Friend began in 2023 and includes Garzulys as well as two additional insulin biosimilar candidates. For Meitheal, the FDA approval of Garzulys strengthens its growing biologics and branded-product strategy while expanding its footprint in the U.S. diabetes market. The company combines its commercial platform with regulatory expertise and international development and manufacturing partnerships to support increasingly complex pharmaceutical products. With exclusive U.S. commercialization rights secured, Garzulys represents an important addition to Meitheal’s portfolio and another FDA-approved biosimilar insulin option for adults and children requiring rapid-acting insulin to manage diabetes mellitus.
Source: Meitheal Pharmaceuticals press release
